| Subcutaneous Administration of Biotherapeutics: An Overview of Current Challenges and Opportunities |
33 |
| Non-pharmacological Effects in Switching Medication: The Nocebo Effect in Switching from Originator to Biosimilar Agent |
25 |
| Selective JAKinibs: Prospects in Inflammatory and Autoimmune Diseases |
25 |
| Mechanisms and Management of Chimeric Antigen Receptor T-Cell Therapy-Related Toxicities |
20 |
| Oncolytic Viruses: Priming Time for Cancer Immunotherapy |
17 |
| Mission Possible: Advances in MYC Therapeutic Targeting in Cancer |
17 |
| Expanding the Boundaries of Biotherapeutics with Bispecific Antibodies |
16 |
| Small-Molecule Immune Checkpoint Inhibitors Targeting PD-1/PD-L1 and Other Emerging Checkpoint Pathways |
15 |
| Spherical Nucleic Acid Nanoparticles: Therapeutic Potential |
14 |
| Chimeric Antigen Receptor-T Cells for Targeting Solid Tumors: Current Challenges and Existing Strategies |
13 |
| Tissue Engineering in Osteoarthritis: Current Status and Prospect of Mesenchymal Stem Cell Therapy |
13 |
| PARP Inhibitors and the Evolving Landscape of Ovarian Cancer Management: A Review |
13 |
| Applications of Bioengineered 3D Tissue and Tumor Organoids in Drug Development and Precision Medicine: Current and Future |
12 |
| First-Line Treatment of Non-Small-Cell Lung Cancer (NSCLC) with ImmuneCheckpoint Inhibitors |
12 |
| Targeting IL-6 or IL-6 Receptor in Rheumatoid Arthritis: What's the Difference? |
11 |
| Indoleamine 3-Dioxygenase (IDO) Inhibition as a Strategy to Augment Cancer Immunotherapy |
11 |
| Evolution of the EU Biosimilar Framework: Past and Future |
11 |
| Anticalin (R) Proteins as Therapeutic Agents in Human Diseases |
11 |
| Humanized Mouse Models for the Preclinical Assessment of Cancer Immunotherapy |
11 |
| Biosimilarity and Interchangeability: Principles and Evidence: A Systematic Review |
11 |
| Immunogenicity of Chimeric Antigen Receptor T-Cell Therapeutics |
10 |
| Emerging Technologies for Delivery of Biotherapeutics and Gene Therapy Across the Blood-Brain Barrier |
9 |
| CDK4/6 Inhibitors Expand the Therapeutic Options in Breast Cancer: Palbociclib, Ribociclib and Abemaciclib |
9 |
| Vestronidase Alfa: A Review in Mucopolysaccharidosis VII |
9 |
| Recombinant Antibody Production in CHO and NS0 Cells: Differences and Similarities |
9 |
| Efficacy and Safety Outcomes for Originator TNF Inhibitors and Biosimilars in Rheumatoid Arthritis and Psoriasis Trials: A Systematic Literature Review |
9 |
| Interleukin-1 Blockade in Cardiovascular Diseases: From Bench to Bedside |
9 |
| Lanadelumab for the Prophylactic Treatment of Hereditary Angioedema with C1 Inhibitor Deficiency: A Review of Preclinical and Phase I Studies |
9 |
| CAR-T Engineering: Optimizing Signal Transduction and Effector Mechanisms |
8 |
| The Relationship between Exosomes and Cancer: Implications for Diagnostics and Therapeutics |
8 |
| Therapeutic Monoclonal Antibodies to Complex Membrane Protein Targets: Antigen Generation and Antibody Discovery Strategies |
7 |
| The End of Phase 3 Clinical Trials in Biosimilars Development? |
7 |
| Comparative Effectiveness and Safety of Monoclonal Antibodies (Bevacizumab, Cetuximab, and Panitumumab) in Combination with Chemotherapy for Metastatic Colorectal Cancer: A Systematic Review and Meta-Analysis |
7 |
| Therapeutic Targeting of the Interleukin-4/Interleukin-13 Signaling Pathway: In Allergy and Beyond |
7 |
| Current Ebola Virus Vaccine Progress |
7 |
| Biological Characterization of SB a Trastuzumab Biosimilar, and the Influence of Changes in Reference Product Characteristics on the Similarity Assessment |
6 |
| Different Cardiotoxicity of Palbociclib and Ribociclib in Breast Cancer: Gene Expression and Pharmacological Data Analyses, Biological Basis, and Therapeutic Implications |
6 |
| Pharmacokinetic and Immunological Considerations for Expanding the Therapeutic Window of Next-Generation Antibody-Drug Conjugates |
6 |
| Comparative Efficacy and Safety of Biosimilar Rituximab and Originator Rituximab in Rheumatoid Arthritis and Non-Hodgkin's Lymphoma: A Systematic Review and Meta-analysis |
6 |
| An Efficient Development Paradigm for Biosimilars |
5 |
| Darvadstrocel: A Review in Treatment-Refractory Complex Perianal Fistulas in Crohn's Disease |
5 |
| Overcoming Tumor-Induced Immune Suppression: From Relieving Inhibition to Providing Costimulation with T Cell Agonists |
5 |
| Budget Impact of Switching to Biosimilar Trastuzumab (CT-P6) for the Treatment of Breast Cancer and Gastric Cancer in 28 European Countries |
5 |
| Adalimumab Biosimilars in Europe: An Overview of the Clinical Evidence |
5 |
| Different Policy Measures and Practices between Swedish Counties Influence Market Dynamics: Part 1Biosimilar and Originator Infliximab in the Hospital Setting |
5 |
| Long-Term Efficacy and Safety of Biosimilar CT-P10 Versus Innovator Rituximab in Rheumatoid Arthritis: 48-Week Results from a Randomized Phase III Trial |
5 |
| Assessing Analytical and Functional Similarity of Proposed Amgen Biosimilar ABP 980 to Trastuzumab |
4 |
| Different Policy Measures and Practices between Swedish Counties Influence Market Dynamics: Part 2Biosimilar and Originator Etanercept in the Outpatient Setting |
4 |
| Monoclonal Antibodies for Multiple Sclerosis: An Update |
4 |
| Real World Data on the Utilization Pattern and Safety Profile of Infliximab Originator Versus Biosimilars in Italy: A Multiregional Study |
4 |
